Home › Funds › Rosalind Advisors, Inc. › XFOR

Rosalind Advisors, Inc. position in XFOR

X4 PHARMACEUTICALS INC · Health Care

Rosalind Advisors, Inc. reported holding 3,214,766 shares of XFOR (X4 PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$15.0M, representing 5.58% of its reported portfolio and ranking #6 among its reported holdings. Rosalind Advisors, Inc. has disclosed XFOR holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

Latest position (Q2 2026)3.21M sh
Reported value held$15.01M
Portfolio Weight5.58%
First reportedQ3 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Rosalind Advisors, Inc.'s XFOR position evolved

Rosalind Advisors, Inc. first disclosed a stake in XFOR in Q3 2025 at 1,544,607 shares (US$5.3M). The position peaked in Q2 2026 at 3,214,766 shares, worth US$15.0M. Across 4 filings, Rosalind Advisors, Inc. increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 3,214,766 shares valued at US$15.0M. Notable position changes include a 69% increase in Q4 2025 (shares rose 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 1.54M $5.28M New
Q4 2025 2.61M $10.42M Add
Q1 2026 3.21M $13.28M Add
Q2 2026 3.21M $15.01M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XFOR and 13F data

XFOR (X4 PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in XFOR — the largest reported positions include Bain Capital Life Sciences Investors, LLC (US$37.2M), PERCEPTIVE ADVISORS LLC (US$37.0M), Saturn V Capital Management LP (US$32.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XFOR

All XFOR fund holders →

FAQ

How long has Rosalind Advisors, Inc. held XFOR?

Rosalind Advisors, Inc. has disclosed XFOR holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

What is Rosalind Advisors, Inc.'s current position in XFOR?

As of Q2 2026, Rosalind Advisors, Inc. holds 3.21M shares of XFOR (X4 PHARMACEUTICALS INC), valued at $15.01M, representing 5.58% of its reported portfolio and ranking #6.

Has Rosalind Advisors, Inc. been buying or selling XFOR?

In the latest 13F filing (Q2 2026), Rosalind Advisors, Inc. held unchanged its position in XFOR. The position peaked in Q2 2026 at 3.21M shares.

Which other funds hold XFOR?

Other major institutional holders of XFOR include Bain Capital Life Sciences Investors, LLC, PERCEPTIVE ADVISORS LLC, Saturn V Capital Management LP, among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.